Dapagliflozin effect on cardiopulmonary function, reverse cardiac remodelling and biomarkers in a cohort of HFrEF patients

Back

HFA Premium Access

Dapagliflozin effect on cardiopulmonary function, reverse cardiac remodelling and biomarkers in a cohort of HFrEF patients

Session: Chronic heart failure - treatment 1

Topic: Treatment

Speaker: Doctor I. Mattavelli (Milan, IT)

Event: Heart Failure 2024

Congress Presentation

Add to my library

About the speaker

Doctor Irene Mattavelli

Monzino Cardiology Centre, Milan (Italy)

0 follower

7 more presentations in this session

Effects of left atrial to coronary sinus shunting on right heart function: the ALT-FLOW early feasibility study (EFS) one-year results

Speaker: Associate Professor M. Urey (San Diego, US)

The efficacy and safety of heart failure treatment according to frailty status; a systematic review.

Speaker: Miss C. Nijskens (Amsterdam, NL)

Heart failure in elderly patients with a recent myocardial infarction and the effect of omega-3 fatty acids: secondary analysis from the OMEMI trial

Speaker: Doctor K. Berge (Oslo, NO)

First-in-human study of left ventricular remuscularization with induced pluripotent stem cell derived cardiomyocyte spheroids for severe ischemic heart failure patients: preliminary LAPiS study result

Speaker: Assistant Professor Y. Ichihara (Tokyo, JP)

Cardiac rhythm management devices in patients with heart failure - preliminary results of the DIRECT HF international survey on healthcare professionals' educational needs

Speaker: Professor S. Zieroth (Winnipeg, CA)

Access the full session

Chronic heart failure - treatment 1

Speakers: Doctor I. Mattavelli, Associate Professor M. Urey, Miss C. Nijskens, Doctor K. Berge, Assistant Professor Y. Ichihara...

Access

About the event

Heart Failure 2024

11 May - 14 May 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources